Renowned Pharmaceutical R&D Expert Jan Lundberg Joins Metabolon’s Board of Directors

RALEIGH, N.C.–(BUSINESS WIRE)–Metabolon, the world leader in metabolomics, today announced that Dr.
Jan Lundberg, Ph.D. has joined its Board of Directors. Dr. Lundberg
brings significant experience leading large global research and
development organizations, most recently as President of Lilly Research
Labs and Head of R&D at Eli Lilly. Lundberg will serve as an independent
director to Metabolon.

Dr. Lundberg is a luminary within the pharmaceutical research and
development community. Dr Lundberg joins the Metabolon Board at a key
time for our company, and his industry experience and scientific
insights will be a valuable asset as we continue to deliver world-class
metabolomics data, solutions and insights,” said Rohan Hastie, Ph.D.,
Chief Executive Officer of Metabolon.

Lundberg has two decades of executive leadership experience in the
pharmaceutical sector and held c-suite positions with leading companies
including Eli Lilly and AstraZeneca. He has overseen the development of
more than 200 candidate drugs, with 22 approved products across multiple
therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the
position of Professor of Pharmacology at the Karolinska Institute in
Solna, Sweden.

Having watched Metabolon over the past few years, the company’s
progress in becoming the global leader in metabolomics has been
formidable,” said Dr. Lundberg. “I am excited to join the Board and look
forward to contributing to the team’s growing success.”

In addition to his significant industry experience, Dr. Lundberg is the
co-founder of Aerocrine AB and currently serves on the boards of
Ardelyx, Betagenon Image Analysis Group, and TB Alliance. He has also
been a member of several governmental committees in both the European
Union and the United States. Dr. Lundberg completed his undergraduate
studies at the University of Gothenburg, earning a Bachelor of Science
degree in Medicine, and his Ph.D. at the Karolinska Institute.

About Metabolon

Metabolon is the world’s leading health technology company advancing
metabolomics for precision medicine and every area of life sciences
research. Metabolon’s Precision Metabolomics™ is a powerful technology
for assessing health and is delivering biomarker discoveries, innovative
diagnostic tests, and ground-breaking data in genomics and population
health initiatives.

Almost every factor impacting the phenotype — from genetics and the
microbiome to disease and lifestyle — exerts its influence by altering
metabolite levels. By producing the most accurate, comprehensive picture
of the metabolome, Metabolon helps answer some of biology’s most
challenging questions.


Ben Marcus

error: Content is protected !!